Royalty Pharma shares rise 5.76% intraday after Q3 2025 results beat estimates, raising full-year guidance and announcing $310M Alnylam royalty acquisition.

Royalty Pharma surged 5.76% intraday following the release of its third-quarter 2025 results, which showed 11% year-over-year growth in Portfolio Receipts to $814 million, driven by strong royalty receipts from key products like Voranigo, Tremfya, and the cystic fibrosis franchise. The company raised full-year 2025 guidance to $3.2–3.25 billion in Portfolio Receipts (up from $3.05–3.15 billion), reflecting confidence in its expanding portfolio and capital deployment strategy. Recent transactions, including a $950 million acquisition of a royalty on Amgen’s Imdelltra and a $300 million funding agreement for Zenas BioPharma’s obexelimab, underscored its aggressive growth initiatives. Additionally, $1.2 billion in share repurchases year-to-date and positive clinical updates for therapies like daraxonrasib and trontinemab reinforced investor optimism. The stock’s intraday rally aligned with the earnings beat, guidance upgrade, and strategic investments highlighting its leadership in biopharma royalties.